Treating spondyloarthritic and psoriatic conditions with upadacitinib

Provided is the JAKI inhibitor upadacitinib free base or a pharmaceutically acceptable salt thereof for use in methods for treating various spondyloarthritic and psoriatic conditions, including types of axial spondyloarthritis (axSpA), psoriatic arthritis (PsA), and psoriasis (PsO). In various aspec...

Full description

Saved in:
Bibliographic Details
Main Authors ANDERSON, Jaclyn Kay, PANGAN, Aileen L, SONG, In-Ho, ENEJOSA, Jose Jeffrey V
Format Patent
LanguageEnglish
Published 21.04.2022
Subjects
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:Provided is the JAKI inhibitor upadacitinib free base or a pharmaceutically acceptable salt thereof for use in methods for treating various spondyloarthritic and psoriatic conditions, including types of axial spondyloarthritis (axSpA), psoriatic arthritis (PsA), and psoriasis (PsO). In various aspects, upadacitinib free base or a pharmaceutically acceptable salt thereof is for use in methods for treating active non-radiographic axSpA (nr-axSpA), methods for treating active ankylosing spondylitis (AS), methods for treating active psoriatic arthritis (PsA), and methods for treating active psoriasis (PsO).
Bibliography:Application Number: AU20200359635